Skip to Content

Label Changes for:

Accolate (zafirlukast) tablets

August 2009

Changes have been made to the PRECAUTIONS and ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- August 2009


  • Neuropsychiatric Events was added as a separate subsection


  • Neuropsychiatric adverse events with the terms “depression” and “insomnia” were added